Navigation Links
OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Date:6/26/2012

r this year."

About OMS-I100

A total of up to 25 patients with Stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label, and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days one, five and eight with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.

About Melanoma

The incidence of many common cancers is falling, but the incidence of melanoma continues to rise at a rate faster than that of any of the seven most common cancers. Between 1992 and 2004, melanoma incidence increased 45 percent, or 3.1 percent annually. An estimated 68,000 new cases of melanoma were diagnosed in the U.S. in 2010 — with nearly 8,700 resulting in death. Approximately 75 percent of skin cancer deaths are from melanoma. In 2004, the most recent figures available, the total direct medical cost associated with the treatment of skin cancer in the U.S. was $1.5 billion. Currently there are few treatment options for metastatic melanoma because of  the aggressive nature of the disease. Current treatment approaches are associated with high morbidity and only marginal improvements in overall survival.

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that are able to minimize detrimental effec
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
5. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
6. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
7. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
8. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
9. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
10. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
11. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
(Date:7/30/2014)... , July 30, 2014 Silicon Valley Bank, ... a study today that examines the merger, acquisition ... device companies.  According to the annual report based on ... potential returns since SVB started tracking the data in ... IPO.  Built on solid healthcare M&A activity over the ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:7/30/2014)... The Europe commercial aviation actuation system market ... is expected to reach $1,686.72 million by 2019 at ... an exclusive range of opportunities and challenges which will ... has seen slumps in the past, yet the sector ... to its long-term growth rate of approximately 5 % ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Foot ... Seminar schedule, a series highlighted by eight speakers, 29 ... from seven chiropractic colleges. The seminars cover a range ... from low back stabilization to imaging. The Foot ... professionals by providing informative, entertaining courses that also offer ...
(Date:7/30/2014)... N.J. The household income of its residents is ... or low rates of avoidable hospital visits conditions that ... health care settings if treated at an early stage, according ... State Health Policy (CSHP). , An analysis of hospital ... low-income communities in New Jersey found that as an area,s ...
(Date:7/30/2014)... It is said that necessity is the ... true as a product sponsor for Lash Wars 2014 ... past June. , Lash Affair believes in the ... the eyelash industry through collaboration so Jenelle Paris, Founder and ... NEESA ’s event. Lash Affair’s mission dovetails nicely with ...
(Date:7/30/2014)... one in every twenty elderly American adults is being ... This burgeoning public health crisis especially affects poor and ... makers, researchers, and any citizen who cares about the ... Peterson of Weill Cornell Medical College in the US. ... on elder abuse, the findings of which appear in ...
Breaking Medicine News(10 mins):Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4Health News:Foot Levelers Announces 2014 Fall Seminars Series Schedule 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 3Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Older adults are at risk of financial abuse 2
... International SOS Assistance, Inc. today was awarded the ... Department of Defense TRICARE Overseas Program. Since 1998, International SOS ... and their families receive the highest quality care, no matter ... States and Puerto Rico. , Under this new ...
... given early in pregnancy might save infants most at ... -- U.S. researchers are testing a new approach in ... while they,re still in the womb. , The new ... cells that have been treated to speed and improve ...
... 16 The National Trauma Institute, a national non-profit ... States, announced its first Request for Proposals (RFP) for ... practice and save lives. , The organization will award ... take place in 2010. "Historically, trauma research has been ...
... THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 16 ... PFE ), today announced new scientific data about ENBREL ... (ACR) Scientific Meeting in Philadelphia, Pa., from Oct. 17-21, ... years of collective clinical experience. , "The ...
... public forum for discussing the latest updates, information on H1N1/Swine flu ... public are invited to submit questions for inclusion in a two-part ... 22, from 10 a.m. - noon on Twitter. , Sandro ... Health System and VA Ann Arbor Healthcare System, will answer questions ...
... comment on media reports this week that France is ... internet, to conform to European rights. Although Budget Minister ... news is disappointing given the drop in heart attack ... Professeur Ph.Gabriel STEG (Universit Paris VII, Centre Hospitalier Bichat-Claude ...
Cached Medicine News:Health News:International SOS Awarded TRICARE Overseas Program Contract 2Health News:Transplant May Treat Metabolic Disorders in Womb 2Health News:National Trauma Institute Announces $600,000 in Funding for Trauma Research 2Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 2Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 3Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 4Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 5Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 6Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 7Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 8Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 9Health News:ESC press statement : Cigarettes on sale on the internet 2Health News:ESC press statement : Cigarettes on sale on the internet 3
... technology makes BURANE XL a ... array of aesthetic laser applications. ... controllable mode for coagulation, an ... procedures, and in particular a ...
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Used for cystometry and urethral pressure profilometry. A loop is employed to enhance catheter retention and stabilization within the bladder. Supplied sterile in peel-open packages. Intended for one...
Medicine Products: